New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
Tools›Compare›Vesilute vs Vilon

Vesilute vs Vilon

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesilute
Immune SupportAnti-Aging & Longevity
Vilon
Summary
Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
Vilon is a synthetic dipeptide (Lys-Glu) derived from the thymus gland extract Thymalin. The shortest immune-regulatory peptide known, Vilon modulates T-cell and NK-cell function, extends lifespan in animal models, and shows epigenetic anti-aging activity. It is one of the Khavinson peptide bioregulators.
Half-Life
Short (minutes); sustained gene-regulatory effects
Very short as a free dipeptide; effects mediated via gene regulation
Admin Route
SubQ, Oral
SubQ, Oral
Research
—
—
Typical Dose
10 mg per day
1–2 mg SC daily or 5–10 mg oral daily
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
  • Immune system modulation and restoration
  • Lifespan extension (30–40% in animal studies)
  • T-cell and NK-cell activation
  • Epigenetic anti-aging activity
  • Reduces oxidative stress markers
  • Antioxidant gene upregulation
  • May prevent age-related immune senescence
  • Anti-tumor immune surveillance
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses
  • Excellent safety profile, decades of Russian clinical use
  • Rare: mild injection site reaction
  • Very rare: mild allergic reaction
Stacks With
—
—